![](https://webarchive.library.unt.edu/web/20090117032250im_/http://www.fda.gov/cder/templates/graphics/dot_clear.gif) |
Lotronex (alosetron hydrochloride) Information
FDA announced June 7, 2002 the approval of a supplemental New Drug Application (sNDA) that allows restricted marketing of Lotronex (alosetron hydrochloride), to treat only women with severe diarrhea-predominant irritable bowel syndrome (IBS). The approved sNDA for Lotronex includes a risk management program to ensure patients and physicians are fully informed of risks and possible benefits of Lotronex.
Do Not Buy Lotronex Over the
Internet
- You should not buy Lotronex over the Internet because you
will bypass important safeguards designed to protect your
health (and the health of others).
- Lotronex has special safety restrictions on how it is
distributed to the public. Also, drugs purchased from foreign
Internet sources are not the FDA-approved versions of the
drugs, and they are not subject to FDA-regulated manufacturing
controls or FDA inspection of manufacturing facilities.
To learn more about buying drugs safely, please see
|
Current Information
Background Information
Back
to Top Back to Drug Information
PDF requires the free Adobe Acrobat Reader
Date created: December 18, 2000, updated May 6, 2008
|
![](https://webarchive.library.unt.edu/web/20090117032250im_/http://www.fda.gov/cder/templates/graphics/dot_clear.gif) |